Yan Shushan, Xu Donghua, Jiang Tao, Wang Ping, Yin Yin, Wang Xiaochen, Hua Changjiang, Zhang Bin, Li Zengcai, Lu Lei, Liu Xianzhong, Wang Bingji, Zhang Donghua, Zhang Rongsheng, Sun Beicheng, Wang Xuan
Department of Surgical Oncology, The Eighty-First Hospital of People's Liberation Army, Nanjing, Jiangsu Province, 210002, China.
Tumour Biol. 2014 Sep;35(9):8927-32. doi: 10.1007/s13277-014-2127-2. Epub 2014 Jun 4.
Cluster of differentiation 24 (CD24) has been implicated in the development of cancer. Several single nucleotide polymorphisms (SNPs) in CD24 gene are reported to exert diverse effect on cancer risk. However, the association between CD24 SNPs and cancer risk remains unclear due to contradictory published findings. We performed a meta-analysis by pooling all available published studies on the susceptibility of CD24 rs52812045 and rs3838646 polymorphisms to cancer. The pooled odds ratios (ORs) with 95 % confidence intervals (95 % CIs) were calculated. There were five independent case-control studies with 5,539 cases and 10,241 controls included into the present study. The pooled results showed that no appreciable relationship was identified between any of the SNPs of CD24 and cancer risk. Interestingly, a protective role of the CD24 rs3838646 polymorphism was found in the risk of breast cancer, but lack of statistical significance (del allele vs. TG allele: OR = 0.89; 95 % CI, 0.79-1.01; P OR = 0.063; del/del vs.
TG/TG: OR = 0.70; 95 % CI, 0.44-1.12; P OR = 0.135; del/TG vs.
TG/TG: OR = 0.91; 95 % CI, 0.80-1.04, P OR = 0.180; del/del + del/TG vs.
TG/TG: OR = 0.90; 95 % CI, 0.79-1.03; P OR = 0.123; del/del vs. TG/TG + del/TG: OR = 0.69; 95 % CI, 0.44-1.08, P OR = 0.105). Our study firstly provides the evidence that SNPs (rs52812045 and rs3838646) of CD24 may not modify the risk of cancer. Nonetheless, more individual studies with high quality are needed for further elucidation.
分化簇24（CD24）与癌症的发生发展有关。据报道，CD24基因中的几个单核苷酸多态性（SNP）对癌症风险有不同影响。然而，由于已发表的研究结果相互矛盾，CD24 SNP与癌症风险之间的关联仍不明确。我们通过汇总所有已发表的关于CD24 rs52812045和rs3838646多态性对癌症易感性的研究进行了一项荟萃分析。计算了合并比值比（OR）及其95%置信区间（95%CI）。本研究纳入了5项独立的病例对照研究，共5539例病例和10241例对照。汇总结果显示，未发现CD24的任何SNP与癌症风险之间存在明显关联。有趣的是，发现CD24 rs3838646多态性对乳腺癌风险有保护作用，但缺乏统计学意义（缺失等位基因与TG等位基因：OR = 0.89；95%CI，0.79 - 1.01；P OR = 0.063；缺失/缺失与TG/TG：OR = 0.70；95%CI，0.44 - 1.12；P OR = 0.135；缺失/TG与TG/TG：OR = 0.91；95%CI，0.80 - 1.04，P OR = 0.180；缺失/缺失 + 缺失/TG与TG/TG：OR = 0.90；95%CI，0.79 - 1.03；P OR = 0.123；缺失/缺失与TG/TG + 缺失/TG：OR = 0.69；95%CI，0.44 - 1.08，P OR = 0.105）。我们的研究首次提供了证据表明CD24的SNP（rs52812045和rs3838646）可能不会改变癌症风险。尽管如此，仍需要更多高质量的个体研究来进一步阐明。
